MAE Group Partners with Monterail to Bring Regulatory Strategy into HealthTech Development

Announcement

By Janet Kwiatkowski, Founder, President & CEO, MAE Group

I’ve spent over 25 years in medical devices, including roles at Medtronic, Hologic, and Millipore, and I founded MAE Group in 2013. In that time I’ve watched the same story play out more often than I’d like to admit.

A team builds a product that works. The engineering is solid and the clinical need is real. Then, somewhere close to submission, a regulatory question comes up that nobody asked early enough. Suddenly a technically sound product is headed back into redesign, the timeline slips, and the budget stretches to cover work that has to be done twice.

That is almost never a talent problem. It’s a timing problem.

That’s why I’m proud to share that MAE Group has formed a strategic partnership with Monterail, a software development company with more than 75 healthcare products and 15+ regulated devices behind it. MAE Group is now part of the Monterail Universe, their network of independent specialist partners covering regulatory, clinical, hardware, legal, and market access work.

Janet Kwiatkowski and Piotr Zając on why engineering and regulatory strategy belong together.

Why timing matters so much

In regulated HealthTech, the software is only one piece of what has to be ready. Intended use, device classification, clinical validation, quality systems, and reimbursement strategy all shape what the product needs to do and how it needs to be documented.

When those decisions come after the architecture is already set, teams discover that their data flows, audit trails, or feature scope don’t line up with what their regulatory pathway requires. Fixing that late is always more expensive than building it right the first time.

Our partnership with Monterail brings regulatory, clinical, and commercial requirements into product development early, while teams still have room to respond.

How we work together

MAE Group and Monterail remain independent companies with clear roles.

Builds

Monterail

Software built to recognized standards such as IEC 62304 and ISO 13485, with audit-ready documentation.

Guides

MAE Group

Regulatory strategy, submissions, and work with regulators, plus clinical, quality, and commercialization support.

Owns

You

As the legal manufacturer, you keep ownership of your regulatory file and your final submission.

In practice, this means architecture choices get checked against your regulatory pathway before they’re locked in, and your documentation is produced in the format your submission will actually need. One coordinated team, from concept to market.

Who this partnership is built for

We see three kinds of companies get the most value from having development and regulatory expertise at the same table:

  • Early-stage founders still working out whether their product is software as a medical device (SaMD) or a wellness app. That answer needs to come before you commit to an architecture.
  • Teams with a working proof of concept that now needs to become a regulated product. The decisions you make next will become either a head start or a costly rewrite.
  • Established healthcare and medtech companies entering the US market, where FDA expectations for software documentation and quality systems shape the development plan from the start.

Where the conversation starts: architecture as evidence

Piotr Zając, HealthTech Director at Monterail, and I kicked off our joint content series with an article on how software architecture becomes your regulatory evidence for SaMD FDA submissions.

The core idea is one I share with every client: most of what FDA requires already comes out of disciplined engineering. Traceability, configuration management, verification and validation, risk management under ISO 14971, and modular design all map directly to what a reviewer evaluates during their assessment of a regulatory submission. The strongest submissions are the ones where a reviewer can follow the story from requirement to design to test without having to piece it together from separate documents.

AI raises the stakes further. If you call your product AI-enabled, you need to be ready to explain what the AI does, how it was developed and validated, and how you’ll control it as the product evolves.

“

In a medical device, “AI” isn’t a marketing adjective. It’s a technology you have to stand behind.

Janet Kwiatkowski, Founder, President & CEO, MAE Group

Where does your product stand today?

The hardest part of all this is seeing your own gaps clearly. So we built a free readiness self-assessment for teams developing SaMD, AI-enabled medical technology, and software-enabled devices.

6

areas, from claims and pathway to architecture, evidence, AI, and funding

38

plain-language statements you mark Done, In progress, or Not started

1

instant Green, Yellow, and Red profile with your priority gaps to tackle next

Let’s talk

If you’re building a medical device, an in vitro diagnostic (IVD), or SaMD and want regulatory strategy working alongside your development from the start, I’d love to hear where you are in the process.

Start a conversation with MAE Group

Read Monterail’s announcement of our partnership here.

Janet Kwiatkowski, Founder, President & CEO of MAE Group

About the author

Janet Kwiatkowski

Founder, President & CEO, MAE Group

Janet founded MAE Group in 2013 to help medical device, in vitro diagnostic, and regulated digital health companies turn promising technologies into evidence-supported products and scalable businesses. Her leadership experience spans regulatory, clinical, and quality strategy, engineering and operations, global trade compliance, due diligence, commercialization, and capital formation, including regulatory and quality leadership at Medtronic. She also serves as an expert witness in medtech matters.

Janet holds an MS in Regulatory Affairs for Drugs, Biologics, and Medical Devices, an MBA, a BS in Mechanical Engineering, and an AS in Computer Electronics.

Connect with Janet on LinkedIn

Scroll to Top